Ali Arar

miR-21-3p/IL-22 Axes Are Major Drivers of Psoriasis Pathogenesis by Modulating Keratinocytes Proliferation-Survival Balance and Inflammatory Response

Florence Abdallah, Elodie Henriet, Amandine Suet et al. · Cells · 2021 · 26 citations · Full text

Life Sciences, Dermatology, Molecular Biology +17

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

Sabine Käyser, Richard F. Schlenk, Delphine Lebon et al. · Haematologica · 2021 · 23 citations · Full text

Medicine, Hematology, Oncology +17

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Félix López Cadenas, Eva Lumbreras, Teresa González et al. · Blood · 2022 · 18 citations

Medicine, Hematology, Pharmacology +4

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

María Diez‐Campelo, Félix López Cadenas, Blanca Xicoy et al. · The Lancet Haematology · 2024 · 16 citations

Medicine, Hematology, Pharmacology +13

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Félix López Cadenas, Eva Lumbreras, Blanca Xicoy et al. · Blood · 2020 · 10 citations

Medicine, Hematology, Oncology +7